[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biologics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biologics":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100620828","a-cohort-study-of-the-efficacy-and-safety-of-biologics-in-patients-with-abpa-100620828",false,"NCT07362693","A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).\n2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.\n3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.\n4. Blood eosinophil count ≥150 cells \u002FμL.\n5. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;\n2. Known allergic history to biological agents;\n3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;\n4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n5. Pregnant or lactating women;\n6. Currently participating in other interventional clinical research;\n7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","2 Years","OBSERVATIONAL","To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.",[25,26,27,28,29,30],"ABPA","Biologics","Allergic Bronchopulmonary Aspergillosis (ABPA)","Cohort Study","Allergic Bronchopulmonary Aspergillosis","Efficacy and Safety",[32,29,26],"abpa","RECRUITING","2026-04-16",{"date":36,"type":37},"2026-04-17","ACTUAL",{"date":39,"type":37},"2025-01-31",{"date":41,"type":20},"2028-12-31",{"name":43,"class":44},"Qianfoshan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100596322","phase-1-a-phase-1b2a-study-of-budoprutug-in-subjects-with-immune-thrombocytopenia-itp-100596322","NCT07043946","A Phase 1b\u002F2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)","A Phase 1b\u002F2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects With Immune Thrombocytopenia (ITP)","Inclusion Criteria:\n\n1. Aged 18 years at the time of consent.\n2. Platelet count \\\u003C 30,000\u002FµL despite an adequate trial of at least one prior therapeutic attempt. Platelet counts of \\\u003C 30,000\u002FµL must be confirmed on 2 occasions at least 5 days apart, but no more than 14 days apart.\n3. Partial thromboplastin time \\\u003C 1.5 x upper limit of normal (ULN), prothrombin time \\\u003C 1.5 x ULN, total bilirubin \\\u003C 1.5 x ULN unless due to Gilbert's syndrome, or an international normalized ratio \\\u003C 1.5 at screening.\n\nExclusion Criteria:\n\n1. CD19+ B cell count \\\u003C 80 cells\u002FµL at Screening, or \\\u003C 40 cells\u002FµL if B-cell depleting therapy was received within 24 weeks to 2 years prior.\n2. Diagnosis of paroxysmal nocturnal hemoglobinuria, Evan's Syndrome, or other bleeding disorders affecting safety or data integrity.\n3. Prior B-cell depleting therapy (e.g., rituximab) within 24 weeks before first dose or planned during the study.\n4. Chronic use of anticoagulants or antiplatelet agents (e.g., aspirin, NSAIDs, thienopyridines) within 14 days before dosing through follow-up. Intermittent NSAID use is allowed.\n5. Immunosuppressants (excluding corticosteroids) within 30 days or 5× half-life before Screening; alkylating agents within 180 days.\n6. IVIg treatment within 90 days prior to Screening.\n7. Active ITP treatment (other than steroids or TPO agonists) within 30 days or 5× half-life before first dose, unless approved by Medical Monitor.\n8. Active, chronic, or latent infections including hepatitis B\u002FC or HIV.\n9. Active TB or high TB risk.",{"count":54,"type":20},24,"INTERVENTIONAL",[57,58],"PHASE1","PHASE2","The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.",[61,62,26,63,64],"Immune Thrombocytopenia (ITP)","ITP","Monoclonal","Anti-CD19","2026-03-24",{"date":67,"type":37},"2026-03-27",{"date":69,"type":37},"2025-06-30",{"date":71,"type":20},"2028-08",{"name":73,"class":74},"Climb Bio, Inc.","INDUSTRY",20,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":55,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100604459","phase-4-a-multi-center-rct-clinical-trial-on-personalized-precision-medicine-for-patients-with-psoriasis-and-psoriatic-arthritis-and-investigation-on-cardiovascular-biomarkers-100604459","NCT07149792","A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","SMILE","Inclusion Criteria:\n\n* Healthy subjects\n* Psoriasis patients\n* Psoriatic arthritis patients\n* Agree to provide a blood sample\n\nExclusion Criteria:\n\n* A current history of cancer,\n* Recent hospitalization for infection or current antibiotic treatment\n* HIV infection.",true,"75 Years",{"count":19,"type":20},[87],"PHASE4","The inclusion criteria for this study were patients aged 18 to 75 years with a confirmed diagnosis of psoriasis by a dermatologist or psoriatic arthritis by a rheumatologist. Patients with active infections or suspected malignancies were excluded.\n\nA total of 40 patients with psoriasis, with or without psoriatic arthritis, were enrolled from multiple centers in Taiwan. All participants were recruited from the outpatient clinics of either the Department of Allergy, Immunology, and Rheumatology or the Department of Dermatology in tertiary hospitals across Taiwan.\n\nParticipants were randomly assigned to one of two groups:\n\nPrescreen Strategy-Based Biologics Selection Group\n\nStandard-Based Biologics Selection Group\n\nPatients will be followed up at weeks 4, 8, 12, 24, 32, 40, 48, 56, 64, and 72. Follow-up may be extended up to 3 years if necessary.\n\nClinical assessments will include:\n\nPrimary endpoints: PASI (Psoriasis Area and Severity Index), painful joint count, swollen joint count, and DAPSA (Disease Activity in Psoriatic Arthritis) score.\n\nSecondary endpoints: DLQI (Dermatology Life Quality Index), BSA (Body Surface Area), pruritus score, and internal carotid artery thickness measured at 6 months, 1 year, and 2 years.",[90,91,26],"Psoriasis","Psoriasis Arthritis",[93],"Prescreen, Biologics, Psoriasis, Strategic selection, Psoriatic arthritis","2025-08-24",{"date":96,"type":37},"2025-09-02",{"date":98,"type":37},"2025-07-29",{"date":100,"type":20},"2028-06-01",{"name":102,"class":44},"Taichung Veterans General Hospital",2]